Over recent years, chimeric antigen receptor T-cell (CAR-T) therapy has markedly improved outcomes for patients with relapsed or refractory hematological malignancies. Nevertheless, a substantial proportion of patients still experience relapse or progression after treatment, driven by factors including antigen escape,...
Lu-Chen Zhou, Cheng-Cheng Tian, Rui-Qiang Du et al.· Journal of Hematology & Onco...· 0 citations
ZDHHC12 may serve as a candidate pan-cancer prognostic biomarker and its expression was broadly correlated with immune cell recruitment- and activation-related signatures in glioma and in glioma, and was associated with patient prognosis.
Chao Zhang, Da Teng, Yu Wang et al.· Journal of Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.